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MATERIALS AND METHODS 
 
Recombinant protein expression and purification  
Full-length recombinant His6x-tagged human p97 was purified as described (1). Briefly, E. coli 
Rosetta2 (DE3) cells expressing plasmid-encoded p97 were suspended in 50 mM Tris, pH 8.0, 500 mM 
NaCl, 20 mM imidazole, and 0.5 mM DTT. The cells were lysed, and following centrifugation, the 
resulting supernatant was loaded onto a Ni-NTA column and eluted with a linear gradient of imidazole. 
The His-tag was cleaved using TEV protease during dialysis in 25 mM Tris pH 8.0, 150 mM NaCl, 0.5 
mM DTT and the TEV protease and uncleaved p97 was removed by collecting the follow-through from 
a second Ni-NTA column. Tag-free p97 was purified by size-exclusion chromatography in 25 mM Tris 
pH 8.0, 150 mM NaCl, 0.5 mM DTT using a Superdex 200 16/600 GL column, and stored in aliquots at 
-80°C without glycerol. 
 
 Synthesis of UPCDC30245 
 
 
 
 
 
General:  All reactions were performed under an argon atmosphere and all glassware was flame-dried 
prior to use.  Reactions were monitored by TLC analysis (EM Science pre-coated silica gel 60 F254 
plates, 250 µM layer thickness) and visualization was accomplished with a 254 nM UV light.  
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Purifications by chromatography were performed using SiO2 (SiliaFlash® F60, Silicycle) or using an 
ISCO-Rf flash chromatography system. 1H/13C NMR spectra were recorded on Bruker Avance 500/125 
MHz instruments. Chemical shifts are reported in parts per million with the residual solvent peak used 
as the internal standard (1H/13C: CDCl3, 7.26, 77.2 ppm). Chemical shifts were tabulated as follows: 
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quarter, dd = doublet of doublet, dt = 
doublet of triplet, m = multiplet, b = broad, app = apparent), coupling constants, and integration. All 1D 
NMR spectra were processed using Bruker Topspin NMR. IR spectra were obtained on an Identity IR-
ATR spectrometer. LCMS-high resolution LC/MS analyses were completed on a Thermo Scientific 
Exactive spectrometer with purities determined using an Agilent Technologies 385-ELSD using 
MeCN/H2O with 0.1% formic acid.  
 
A solution of 3-bromoacetophenone (2.03 g, 10.2 mmol), p-F-aniline (1.16 g, 10.4 mmol), and 
TsOHH2O (38 mg, 0.20 mmol) in toluene (60 mL) was heated overnight under Dean-Stark conditions. 
The reaction mixture was cooled to room temperature, evaporated, and purified by chromatography on 
SiO2 (ISCO-Rf, 0-10% EtOAc/hexanes) to give (E)-1-(3-bromophenyl)-N-(4-fluorophenyl)ethan-1-
imine as a yellow oil (0.96 g, 3.3 mmol, 32%) that was used without further purification.   
 
A solution of (E)-1-(3-bromophenyl)-N-(4-fluorophenyl)ethan-1-imine (0.853 g, 2.92 mmol), Pd(OAc)2 
(63.0 mg, 0.280 mmol), and Cu(OAc)2 (1.42 g, 5.51 mmol) in DMSO (25 mL) was stirred at room 
temperature overnight	  (2). The solution was diluted with H2O, and extracted with EtOAc. The organic 
layer was washed with brine, dried (Na2SO4), filtered and concentrated. The residue was absorbed onto 
SiO2 and purified by chromatography on SiO2 (ISCO-Rf, 0-10% EtOAc/hexanes) to give 2-(3-
bromophenyl)-5-fluoro-1H-indole as a light yellow solid (0.19 g, 22%). The mixed fractions were 
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absorbed onto SiO2 and subjected to a 2nd chromatography on SiO2 (7/1 hexanes/Et2O) to give 
additional product (0.439 g total, 1.51 mmol, 52%).  
 
A solution of 2-(3-bromophenyl)-5-fluoro-1H-indole (100 mg, 0.345 mmol), K3PO4 (82 mg, 0.38 
mmol), Pd2(dba)3 (4.6 mg, 0.005 mmol), CyJohnPhos (7.0 mg, 0.02 mmol), tert-butyl (2-(4-
isopropylpiperazin-1-yl)ethyl)(piperidin-4-yl)carbamate2 (0.106 g, 0.300 mmol) in anhydrous and 
deoxygenated dioxane (1.5 mL) in a 2-5 mL conical reaction vial was degassed by bubbling argon for 5 
min. The vessel was sealed and heated at 110 °C overnight, cooled to room temperature, diluted with 
sat. NaHCO3, and extracted with CH2Cl2 (3x). The organic layers were combined, washed with brine, 
dried (Na2SO4), evaporated, and purified by chromatography on SiO2 (2% MeOH/CH2Cl2 and 0.1% 
TEA) followed by chromatography on basic Al2O3 (CH2Cl2) to give tert-butyl (1-(3-(5-fluoro-1H-indol-
2-yl)phenyl)piperidin-4-yl)(2-(4-isopropyl-piperazin1-yl)ethyl)carbamate (62 mg, 0.11 mmol, 44%) as a 
pale yellow semi-solid.  
 
A solution of trifluoroacetic acid (1.2 mL, 16.1 mmol) and triethylsilane (0.25 mL, 1.6 mmol) in CH2Cl2 
(1 mL) was added to a solution of tert-butyl (1-(3-(5-fluoro-1H-indol-2-yl)phenyl)piperidin-4-yl)(2-(4-
isopropyl-piperazin1-yl)ethyl)-carbamate	  (3) (88 mg, 0.16 mmol) in CH2Cl2 (0.5 mL). The reaction 
mixture was stirred under an atmosphere of N2 at room temperature for 2 h, concentrated, diluted with 
sat. NaHCO3, extracted with EtOAc (3x). The combined organic layer was washed with brine, dried 
(Na2SO4), filtered and concentrated.  The crude residue was purified by chromatography on SiO2 (8 to 
10% MeOH/CH2Cl2 with 0.1% TEA) followed by chromatography on basic Al2O3 (0 to 10% 
MeOH/CH2Cl2) to afford 1-(3-(5-fluoro-1H-indol-2-yl)phenyl)-N-(2-(4-isopropylpiperazin-1-
yl)ethyl)piperidin-4-amine (UPCDC30245) as a yellow foamy solid (61 mg, 0.13 mmol, 84%).  IR 
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peaks (ATR, neat) 3234, 2960, 2930, 2844, 2814, 2099, 1672, 1640, 1635, 1601, 1584, 1486, 1452, 
1383, 1355, 1199, 1178, 1130 cm-1; 1H NMR shifts (500 MHz, CDCl3) δ 8.89 (s, 1 H), 7.31-7.25 (m, 3 
H), 7.22 (s, 1 H), 7.10	  (d,	  J	  =	  7.5	  Hz,	  1 H), 6.94-6.90 (m, 2 H), 6.74 (d, J = 1.5 Hz, 1 H), 3.73 (app d, J = 
12.5 Hz, 2 H), 2.86-2.77 (m, 4 H), 2.67-2.48 (m, 12 H), 2.01 (d, J = 11.0 Hz, 2 H), 1.54 (qd, J = 12.5, 
2.5 Hz, 2 H), 1.06 (d, J = 6.5 Hz, 6 H); 13C NMR shifts (125 MHz, CDCl3) δ 158.1 (JCF = 234 Hz), 
152.0, 140.6, 133.3, 133.0, 129.7, 129.6 (JCF = 10 Hz), 116.4, 116.1, 113.5, 111.5 (JCF = 9 Hz), 110.2 (JCF 
= 26 Hz), 105.2 (JCF = 24 Hz), 99.8 (JCF = 4 Hz), 58.0, 55.1, 54.5, 53.5, 48.7, 48.6, 43.4, 32.5, 18.7; 19F 
NMR shifts (470 MHz, CDCl3) -124.3; mass spectrometry (ESI) C28H39N5F m/z calculated for [M+H]+ 
464.3184, found 464.3184; ELS purity (100%). 
 
Grid preparation  
Prior to grid preparation, 4 µl of a freshly thawed aliquot of purified p97 was deposited on Quantifoil 
R1.2/1/3 grids and plunge-frozen in liquid ethane cooled by liquid nitrogen. For experiments with added 
inhibitor, the protein was pre-incubated for 30 minutes at room temperature in a solution containing 0.9 
mg/ml p97, 50 µM inhibitor (final 0.3% DMSO, starting from 200 µM stock solution of the compound 
in 1% DMSO), 1 mM MgCl2 and 1 mM TCEP.  For experiments with added ATPγS, the protein was 
pre-incubated for 30 minutes at room temperature in a solution containing 0.9 mg/ml p97, 5mM ATPγS, 
1 mM MgCl2 and 1 mM TCEP.  
 
Data Acquisition 
The grids were imaged using a Titan Krios transmission electron microscope (FEI Company, Hillsboro, 
OR) aligned for parallel illumination and operated at 300 kV, with the specimen maintained at liquid 
nitrogen temperatures. Images were recorded on a K2 Summit camera (Gatan, Inc., Pleasanton, CA) 
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operated in super-resolution counting mode, placed at the end of a GIF Quantum energy filter (Gatan, 
Inc.), functioning in zero-energy-loss mode with a slit width of 20 eV as described previously (4, 5). 
Data was typically collected with a defocus range between -1.0 and -2.0 μm, at a dose rate of ~2.6 e-
/Å2/s at the specimen plane), and a total exposure time of 15.2 s. Intermediate frames were recorded 
every 0.4 s giving an accumulated dose of ~40 e-/Å2 and a total of 38 frames per image.  
 
Image Processing 
Movie frame alignment and CTF estimation for each micrograph were carried out as described 
previously (4). Particles were picked automatically using a Gaussian disk of 85 Å in radius as the search 
template. For data collected with bound inhibitor, 332,805 particles were picked from 2,068 
micrographs and subjected to 8 rounds of refinement in FREALIGN v9.10 (6). The distribution of 
scores assigned to each particle by FREALIGN showed a clear bi-modal distribution and only particles 
in the group containing the higher scores were selected for further processing. This subset of 107,890 
particles was subjected to 46 rounds of 3D classification using 3 classes. Two of the classes showed 
similar high-resolution features and the combined 40,913 particles that were assigned to them were 
subjected to an additional 8 rounds of local refinement. At this point, particles were re-extracted from 
the original micrographs using only the subset of frames 3-16, and used to produce a reconstruction with 
particle orientations derived using the full exposure followed by 8 additional rounds of local refinement 
in FREALIGN. A B-factor of  -75 Å2 was applied to the map for purposes of visualization. 
 
For the unbound p97 structure, 301,685 particles were picked from 1,925 micrographs and subjected to 
8 rounds of refinement. The distribution of FREALIGN scores also showed a bi-modal distribution and 
the 157,840 particles in the group containing higher scores were subjected to 24 rounds of 3D 
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classification using 3 classes. One class was discarded because it did not show high-resolution features 
while the other two represented “primary” and “secondary” conformations containing 69,703 and 59,492 
particles, respectively (Figure S2). Particles assigned to the dominant class that showed the highest-
resolution features were further classified into three sub-classes (30 additional iterations in 
FREALIGN). The subset of 30,616 particles assigned to the most uniform of these classes were 
subsequently re-extracted from the original micrographs using the range of frames 3-16, and used to 
produce a reconstruction with particle orientations derived using the full exposure followed by 8 
additional rounds of local refinement in FREALIGN. A B-factor of -80 Å2 was applied to the map. 
 
For data collected with ATPγS-bound p97, 475,354 particles were selected from 628 micrographs. Eight 
rounds of 3D refinement resulted again in a bimodal distribution of scores and the 203,216 particles 
assigned to the lobe with the highest scores were selected and subjected to 24 rounds of classification 
using 5 classes. Of these, two classes were discarded because they did not show high-resolution features 
and had low numbers of particles. The remaining three classes represented distinct conformational states 
of ATPγS-bound p97: conformation I (70,330 particles), conformation II (61,909 particles), and 
conformation III (52,743 particles). These three sets of particles were each subjected to an additional 
round of 3D classification into two sub-classes (24 additional iterations in FREALIGN). In all three 
cases one of the two sub-classes showed better defined features and particles corresponding to the best 
sub-class in each set (corresponding to 33,882, 32,406, and 23,306 particles for conformations I, II and 
III, respectively) were re-extracted from the original micrographs using the subset of frames 3-16 and 
used to produce the final reconstructions with the alignments derived using the full exposure followed 
by 8 additional rounds of local refinement in FREALIGN. A B-factor of -85 Å2 was applied to the three 
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maps. Refinement was also carried without imposing six-fold symmetry, resulting in the same three 
main classes as observed upon imposition of six-fold symmetry (Figure S9).  
 
Structure refinement  
The structure of p97 reported from earlier X-ray studies (PDB ID 3CF3) containing ADP in both 
nucleotide-binding regions was used as a rough starting model to initiate refinement. Using the program 
Chimera	  (7), the N, D1 and D2 domains were placed separately into the map to get this initial structure 
and the atomic model was rebuilt manually for the entire polypeptide as described below. For the 
UPCDC30245-bound structure, the inhibitor was first manually docked into the additional density. 
Subsequently, the entire structure was refined further in the same way as that of native p97 including 
real-space refinement using the programs COOT	  (8) and PHENIX (9). The fit of the model to the map 
was analyzed and then subjected to reciprocal space refinement using PHENIX. Rigid-body fitting was 
used to refine the individual domains, followed by several rounds of positional and isotropic B-factor 
refinement and geometry minimization. Six-fold symmetry was imposed during refinement steps and 
solvent molecules were added at the end. The resulting atomic model was examined in COOT and 
manual changes were made to selected residues as needed, guided by the density map. The progress of 
refinement was monitored by the analysis of the results using the program Molprobity	  (10).  
 
The initial models for refinement of p97 structures in the presence of ATPγS and intrinsically bound 
ADP were based on the identity of the nucleotides present in the various nucleotide-binding regions of 
the D1 and D2 domains. For the refinement of the conformational states (I and II) that demonstrated 
either the presence of ADP molecules in both domains, or ADP in D1 and ATPγS in D2, the high-
resolution p97 structure with ADP bound was used as the starting model. The respective nucleotides 
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were docked manually into density. The refinement strategy was identical to that described above for 
native p97. For the conformational state that exhibited the presence of ATPγS in both domains, an initial 
model for refinement was created by combining the amino acid residues corresponding to D1 (12-462) 
from PDB ID 3HU1, and D2 (463-763) from PDB ID 3CF3. This hybrid model was initially fitted by 
sequential rigid-body refinement that individually refined the spatial fits of the two domains 
independently. Thereafter, the ATPγS molecules were placed into density in their respective binding 
pockets and subjected to local real-space refinement.   
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Figure S1
Structure of full-length p97 at 2.4 Å resolution. (A) Cryo-EM derived density map with the N 
(green), D1 (blue) and D2 (purple) domains highlighted. (B) Ribbon model of cryo-EM derived 
structure of p97, color-coded as in (A). (C, D) Density for bound ADP in D1 and D2 domains, 
respectively (shown in cyan). Water molecule (red) highlighted in yellow color.
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Figure S2 
Intermediate stages in structure determination of wild-type p97. (A) Raw cryo-EM image 
displaying p97 hexamers in dierent orientations; several representative molecular images 
are circled. (B) Reference-free 2D class averages showing that both top and side views are 
represented in the data. (C, D) Sections through cryo-EM density map of native p97 for the 
primary (C) and secondary (D) classes. The rst section is a horizontal slice through the lower 
D1 domain, while the second and third sections are orthogonal cuts through the center of the 
map showing side views. (E, F) Perspective views of molecular surface models showing the 
locations of the three planes used to produce the sectional images shown in panels (C) and 
(D). The maps show that the D1 and N domains display similar structures in the two 
conformational classes, but the density of the D2 domain is more diuse in the class shown in 
(D), consistent with greater exibility. The arrows in (D) indicate the locations of subtle 
differences in conformation of the D2 domain between the two classes. Slices in this figure 
were generated from uncorrected maps, and the images enable identification of both 
ordered and fuzzy secondary structural elements in the two classes. A total of 69,703 and 
59,492 particles were distributed into the primary and secondary classes, respectively. A 
subset of the particles that contributed to the dominant class (30,616 out of 69,703 particles) 
was used to produce the map of native p97 at 2.4 Å resolution shown in Figure S1. The minor 
class produced a map at lower resolution (~ 3.5 Å). 
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Figure S3
Chemical structure of the inhibitor UPCDC30245 used in this study.
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Figure S4
B-factor analysis of the structure of p97 bound to UPCDC30245. (A) Stereo view of the p97 
protomer, color-coded to indicate variation in B-factors in the rened structure from low 
(blue) to high (red). (B) Graphical representation of the average B-factors plotted against the 
protein sequence. The amino acid residues encompassing the various domains are indicated.
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Figure S5
Comparison of the structures of p97 in the absence and presence of the UPCDC30245 
inhibitor. (A) Stereo view of the p97 protomer shown in ribbon representation, with the N, D1 
and D2 domains of native p97 color coded as in Figure 1, and the inhibitor-bound structure 
shown in grey.  The two structures are very similar with an overall main chain RMSD of 0.84 Å. 
(B, C) Comparison of the ADP binding sites shows that there are only minimal dierences 
between the two structures even at the nucleotide binding sites. As in (A), the 
inhibitor-bound structure is colored in grey. (D, E) Changes between conformations I to II (D) 
and from II to III (E), color-coded from blue to red to reect the extent of change in structure. 
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Figure S6  
Inhibitor and nucleotide binding sites. (A) Electrostatic surface representation of the inhibitor 
binding pocket. The gure illustrates the cavity into which the phenyl indole end of the 
inhibitor inserts and the charge complementarity on the outer edge which presumably helps 
to stabilize binding of the inhibitor.  (B, C) LIGPLOT renderings of the residue environments of 
ADP bound in D1 and D2 binding sites, respectively. The plots identify all residues in the 
immediate vicinity of the bound nucleotides and show the relevant H-bond distances. 
Supplementary Figure 7
Figure S7
Fourier Shell Correlation (FSC) plots to measure resolution of the cryo-EM maps obtained for 
p97 in the native state, in complex with UPCDC30245, and with ATPS (three conformations). 
Shown in blue are the FSC curve between two semi-independently rened halves of 
inhibitor-bound p97 (solid blue) and FSC curve calculated between the map shown in Figs. 
1-2 and the map computed from the cryo-EM-derived atomic model (dashed blue), both 
showing a resolution value of 2.3 Å at the 0.143 and 0.5 cutos, respectively. FSC curves 
between two semi-independently rened halves are shown for native ADP-bound p97 
(magenta) showing a resolution of 2.4 Å, and for the three conformational states in the 
presence of ATPγS showing resolutions of 3.3 Å (red), 3.2 Å (dark green) and 3.3 Å (pale green) 
for conformational states I, II and III, respectively.
!"#$%&'()!*+'"!#,-,'(&-*+' &)#!$$'(%*+' &%#"-%'(-*+'
.'
/012234567'78/0030'$9:;8<'012234567'78/0030'
=;>:;52/?;>'@' =;>:;52/?;>'@@' =;>:;52/?;>'@@@'
"A#%!)'()&*+'
B' B'
B' B'
A B C
D E F
G H I
Figure S8
Conformation I Conformation II Conformation III
D1, ADP
D2, ADP
D1, ADP
D2, ATPγS
D1, ATPγS
D2, ATPγS
J
Figure S8
Visualization of densities for nucleotides in the three conformational states. (A-C) Densities for 
nucleotides occupying the D1 and D2 domains enable unambiguous assignment to ADP or 
ATPγS. In conformation I, ADP occupies both nucleotide-binding sites. In conformation II, ADP 
is bound to D1, while ATPγS is bound to D2.  In conformation III, ATPγS is bound to both D1 
and D2 domains. The schematic diagram at the center of each panel illustrates the regions 
that undergo conformational changes in the sequential transition from conformation I to III. 
(D-F) Overview of the density maps for each conformation, colored as in Figure 1. (G-I) 
Stabilization of the C-terminal helix of the D2 domain. In the presence of ADP alone 
(conformation I), the model ends at residue 763. In the presence of ATPγS in conformations II 
and III, the stabilization results in traceable density leading to an extension of the model to 
residue 768. (J) Clash between conformation II and inhibitor binding. Stereo view of the 
binding site of UPCDC30245 in conformation I, superposed with conformation II to show that 
the latter conformation is incompatible with binding inhibitor in this position. 
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Figure S9
Sections through cryo-EM density maps of ATPγS -bound p97 conformations rened without 
symmetry imposition. The three major classes that emerged at the end of the renement 
correspond to symmetric structures that are the same as those obtained when six-fold 
symmetry was imposed during renement. Two minor classes (~ 7% and ~ 9%) are also 
observed in which the N-domain is displaced upwards in only some of the protomers 
(indicated by asterisks). The low number of particles assigned to these asymmetric classes 
resulted in resolutions that were not high enough to allow determination of the 
stoichiometry or identity of ligands bound to each monomer. Side and top views of central 
slices through the map are shown for each conformation, with the slices obtained as indicated 
in Figure S2. Numbers of particles assigned to each conformation are indicated in each case. 
This analysis shows that although there is clearly a propensity for asymmetric states, the three 
symmetric states explain the predominant source of variability within the particle population. 
The fact that we can determine the structures of each state to near-atomic resolution 
indicates that there is sucient similarity between the units of each hexamer, at least to a 
resolution of 3.2 Å.
Figure S10
Comparison of 2.3 Å cryo-EM density map with X-ray maps of p97 fragments using X-ray 
crystallography of similar resolution. A) Density map in the vicinity of Lys 251 of the 2.3 Å 
resolution UPCDC30245 bound p97 cryo-EM structure reported here. B) and C) 2Fo-Fc 
maps of the same region from previously published X-ray structures of the N-D1 fragment 
at 2.2 Å resolution (PDB ID: 3HU3) and at 1.98 Å resolution (PDB ID: 4KO8), respectively. 
A B CEMD-3295, 2.3 Å PDB 3HU3, 2.2 Å PDB 4KO8, 1.98 Å
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Supplementary Movie S1: Views from selected regions of the density map of UPCDC30245-bound 
p97.  
 
Supplementary Movie S2: Density maps of the three conformational states in the region close to the 
cytoplasmic face of the central pore.  
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